Cited by 764Cancer-related Molecular PathwaysMultiple and Secondary Primary CancersBRCA gene mutations in cancer

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers

Bougeard, Gaëlle, Renaux-Petel, Mariette, Flaman, Jean-Michel, Charbonnier, Camille, Fermey, Pierre, Belotti, Muriel, Gauthier-Villars, Marion, Stoppa-Lyonnet, Dominique, Consolino, Emilie, Brugières, Laurence, Caron, Olivier, Benusiglio, Patrick R., Bressac-de Paillerets, Brigitte, Bonadona, Valérie, Bonaïti-Pellié, Catherine, Tinat, Julie, Baert-Desurmont, Stéphanie, Frebourg, Thierry·2015·Journal of Clinical Oncology

DOI 10.1200/jco.2014.59.5728

Open this paper in CoChat — free account

Abstract

Purpose: The aim of the study was to update the description of Li-Fraumeni syndrome (LFS), a remarkable cancer predisposition characterized by extensive clinical heterogeneity. Patients and Methods: From 1,730 French patients suggestive of LFS, we identified 415 mutation carriers in 214 families harboring 133 distinct TP53 alterations and updated their clinical presentation. Results: The 322 affected carriers developed 552 tumors, and 43% had developed multiple malignancies. The mean age of first tumor onset was 24.9 years, 41% having developed a tumor by age 18. In childhood, the LFS tumor spectrum was characterized by osteosarcomas, adrenocortical carcinomas (ACC), CNS tumors, and soft tissue sarcomas (STS) observed in 30%, 27%, 26%, and 23% of the patients, respectively. In adults, the tumor distribution was characterized by the predominance of breast carcinomas observed in 79% of the females, and STS observed in 27% of the patients. The TP53 mutation detection rate in children presenting with ACC or choroid plexus carcinomas, and in females with breast cancer before age 31 years, without additional features indicative of LFS, was 45%, 42% and 6%, respectively. The mean age of tumor onset was statistically different (P < .05) between carriers harboring dominant-negative missense mutations (21.3 years) and those with all types of loss of function mutations (28.5 years) or genomic rearrangements (35.8 years). Affected children, except those with ACC, harbored mostly dominant-negative missense mutations. Conclusion: The clinical gradient of the germline TP53 mutations, which should be validated by other studies, suggests that it might be appropriate to stratify the clinical management of LFS according to the class of the mutation.

Integrity signals

Registry

Crossref · 10.1200/jco.2014.59.5728

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database
Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598 · cited 2×
“Dominant-negative mutations were defined on the basis of the ability of the mutant protein to inhibit the activity of the wild-type p53 protein,(16) as indicated in the International Agency for Research on Cancer TP53 Database.(17)”
Method
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545
Soft-Tissue Sarcomas, Breast Cancer, and Other Neoplasms
Li, F. P., & FRAUMENI, J. F. (1969) · Annals of Internal Medicine · doi:10.7326/0003-4819-71-4-747 · Cited by 1,514
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308
A cancer family syndrome in twenty-four kindreds.
Li, F. P., Fraumeni, J. F., Mulvihill, J. J., Blattner, W. A., Dreyfus, M., Tucker, M., & Miller, R. (1988) · PubMed · Cited by 1,293
Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome
Srivastava, S. K., Zou, Z., Pirollo, K. F., Blattner, W. A., & Chang, E. H. (1990) · Nature · doi:10.1038/348747a0 · Cited by 1,210
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome
Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069
Beyond Li Fraumeni Syndrome: Clinical Characteristics of Families With p53 Germline Mutations
Hagman, K. D. F., Noltner, K., Buzin, C. H., Gu, D., Wen, C. Y., Nguyen, V. Q., Han, J., Lowstuter, K. J., Longmate, J., Sommer, S. S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6959 · Cited by 607
Multiple Primary Cancers in Families With Li-Fraumeni Syndrome
Hisada, M., Garber, J. E., Li, F. P., Fung, C. Y., & Fraumeni, J. F. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.8.606 · Cited by 553

Flagged first, then by citations

Show all 42 references

Research works printed but not linked: 3

Li FP, 1988, Cancer Res, 48, 5358
Nutting C, 2000, Clin Oncol (R Coll Radiol), 12, 300
Spencer SJ, 1999, J Clin Endocrinol Metab, 84, 1110

Sorted by citations

Items 501–600 of 764

Genetic Disorders with Predisposition to Paediatric Haematopoietic Malignancies—A Review
Filipiuk, A., Kozakiewicz, A., Kośmider, K., Lejman, M., & Zawitkowska, J. (2022) · Cancers · doi:10.3390/cancers14153569 · Cited by 3
Peripheral precocious puberty in Li–Fraumeni syndrome: a case report and literature review of pure androgen-secreting adrenocortical tumors
Ryckx, S., Schepper, J. D., Giron, P., Maes, K., Vaeyens, F., Wilgenhof, K., Lefesvre, P., Ernst, C. W., Vanderlinden, K., Klink, D. T., et al. (2023) · Journal of Medical Case Reports · doi:10.1186/s13256-023-03889-y · Cited by 3
Identification of a TP53 Mutation in a Patient With Li-Fraumeni Syndrome and Not Meeting the Revised Chompret Criteria: A Case Report
Iwasaki, M., So, C., & Jinta, T. (2023) · Cureus · doi:10.7759/cureus.40025 · Cited by 2
A Novel Variant in the TP53 Gene Causing Li–Fraumeni Syndrome
Papadimitriou, D. T., Stratakis, C. A., Kattamis, A., Glentis, S., Dimitrakakis, C., Spyridis, G., Christopoulos, P., Mastorakos, G. P., Vlahos, N., & Iacovidou, N. M. (2023) · Children · doi:10.3390/children10071150 · Cited by 2
A systematic review of the prevalence of pathogenic or likely pathogenic germline variants in individuals with FOXO1 fusion‐positive rhabdomyosarcoma
Freyçon, C., Lupo, P. J., Witkowski, L., Budd, C., Foulkes, W. D., & Goudie, C. (2023) · Pediatric Blood & Cancer · doi:10.1002/pbc.30651 · Cited by 2
BRCA1 Intragenic Duplication Combined with a Likely Pathogenic TP53 Variant in a Patient with Triple-Negative Breast Cancer: Clinical Risk and Management
Ea, V., Berthozat, C., Dreyfus, H., Legrand, C., Rousselet, E., Peysselon, M., Baudet, L., Martinez, G., Coutton, C., & Bidart, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116274 · Cited by 2
Molecular pathophysiology of germline mutations in acute myeloid leukemia
Nagata, Y. (2024) · International Journal of Hematology · doi:10.1007/s12185-024-03824-x · Cited by 2
Novel case of ependymoma-like tumor with mesenchymal differentiation harboring ZFTA::RELA fusion in an adult
Yajima, H., Takayanagi, S., Takami, H., Tanaka, S., Nomura, M., Satomi, K., Ikemura, M., Nobusawa, S., Saito, R., Kondo, A., et al. (2024) · Brain Tumor Pathology · doi:10.1007/s10014-024-00489-6 · Cited by 2
Multidisciplinary Tumor Board Evaluation of Pediatric Patients with Adrenocortical Tumors Across Seven International Centers
Riedmeier, M., Schlötelburg, W., Agarwal, S., Biswas, A., Ekinci, S., Faßnacht, M., Fragoso, M. C. B. V., Gonc, E. N., Gültekin, M., Haliloğlu, M., et al. (2025) · Cancers · doi:10.3390/cancers17061014 · Cited by 2
Avances y futuro del tratamiento de los sarcomas
Monsalve, J. A., & Bolaños-Losada, F. (2024) · Medicina · doi:10.56050/01205498.2376 · Cited by 2
Hematologic Malignancy Frequency, Phenotypes, and Outcomes in Li-Fraumeni Syndrome
Vagher, J., Zakas, A. L., Donovan, L. N., Shoger, K., Naumer, A., Bly, J., Smith-Simmer, K. J., Maese, L. D., Schiffman, J. D., Kohlmann, W. K., et al. (2025) · JCO Precision Oncology · doi:10.1200/po-24-00860 · Cited by 2
Risk of a second primary cancer after breast cancer in Southern Spain: a population-based study over 3 decades
Casquero-Sánchez, J., Reyes, L. M. M.-D. L., Rodríguez‐Barranco, M., Petrova, D., Mendoza-García, O., Redondo‐Sánchez, D., González‐Flores, E., & Sánchez, M.-J. (2025) · Maturitas · doi:10.1016/j.maturitas.2025.108647 · Cited by 2
Unmet Supportive Care Needs in Adults With Li–Fraumeni Syndrome: A Mixed‐Methods Study
Kiermeier, S., Maatouk, I., Nees, J., Keymling, M., Richter, J., Dutzmann, C. M., Silchmüller, F., Kratz, C. P., & Schott, S. (2025) · European Journal of Cancer Care · doi:10.1155/ecc/3342369 · Cited by 2
Peripheral blood DNA methylation predicts the early onset of primary tumor in TP53 mutation carriers
Subasri, V., Brew, B., Laverty, B., Erdman, L., Guha, T., Hansford, J. R., Cairney, E., Portwine, C., Elser, C., Finlay, J. L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62894-5 · Cited by 3
The adrenal gland: an evolution of the roles of genetic counsellors and medical geneticists in endocrine cancers
Gallinger, B., Druker, H. A., Gill, A. J., Wasserman, J. D., & Kim, R. H. (2016) · Diagnostic histopathology · doi:10.1016/j.mpdhp.2016.02.002 · Cited by 2
Prédispositions génétiques en oncologie pédiatrique
Bourdeaut, F., & Coupier, I. (2016) · ONCOLOGIE · doi:10.1007/s10269-016-2672-y · Cited by 2
Genotype-Phenotype Analysis in an Indian Family Affected with Li-Fraumeni Syndrome-Role of Genetic Counselling
Chatterjee, M., Chinder, P. S., Mannan, A. U., Sheela, M. L., Mukherjee, U., Choudhury, S., Lo, C., Singh, S., Singh, J., Hazarika, D., et al. (2016) · International Journal of Human Genetics · doi:10.1080/09723757.2016.11886284 · Cited by 2
Radiation-associated Angiosarcoma Mimicking Fallopian Tube High-grade Serous Carcinoma in a Woman With De Novo Li-Fraumeni Syndrome
Crafton, S., Senter-Jamieson, L., Chen, J. L., Copeland, L. J., & Suarez, A. A. (2018) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000502 · Cited by 2
Myelodysplastic/myeloproliferative neoplasm with eosinophilia as a manifestation of Li Fraumeni Syndrome
Turner, S. A., Shaver, A. C., Kovach, A. E., Oluwole, O. O., & Mason, E. F. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1630619 · Cited by 2
Association of intron microsatellite status and exon mutational profiles of TP53 in human colorectal cancer
Liu, X., Feng, D., Huo, X., Xiao, X., & Chen, Z. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.8095 · Cited by 3
[A rhabdomyosarcoma patient from a Li-Fraumeni syndrome family: a case report and literature review].
Xie, Y., Wei‐hong, Z., Hua, Y., Sun, Q., & Wu, P. (2017) · PubMed Central · doi:10.7499/j.issn.1008-8830.2017.12.008 · Cited by 2
Difficulties of Management of Multiple Synchronous Bone Tumors in Li-Fraumeni Syndrome
Huby, M., Brugières, L., Mascard, É., Gaspar, N., Pannier, S., & Aurégan, J.-C. (2019) · Case Reports in Orthopedics · doi:10.1155/2019/8732089 · Cited by 2
Self-citation
Maxillary mesenchymal chondrosarcoma leading to a diagnosis of Li-Fraumeni syndrome
Ventura, E., Dionísio, S., Ferreira, Â., Saleiro, R., Marques, H., Magalhães, M. P., & Monteiro, C. (2019) · Journal of Surgical Case Reports · doi:10.1093/jscr/rjz386 · Cited by 2
Familiärer Brust- und Eierstockkrebs (einschließlich Hormone)
Kast, K., Rhiem, K., & Schmutzler, R. K. (2020) · Der Gynäkologe · doi:10.1007/s00129-020-04697-x · Cited by 2
The features of acute lymphocytic leukemia with intracranial germinoma in a patient with Li-Fraumeni syndrome: a case description
Liang, Y., Wei, K., & Cao, W. (2021) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims-21-614 · Cited by 2
Psychological Impact of TP53-Variant-Carrier Newborns and Counselling on Mothers: A Pediatric Surveillance Cohort
Gozdziejewski, A. S., Zotti, C. W., de Carvalho, I. A. M., dos Santos, T. C., Walter, L. R. D. S., Ogradowski, K. R. P., Dammski, K. L., Komechen, H., Mendes, M. C., de Souza, E. N., et al. (2022) · Cancers · doi:10.3390/cancers14122945 · Cited by 2
Environmental Contaminants Modulate Breast Cancer Development and Outcome in TP53 p.R337H Carriers and Noncarriers
Gerber, V. K. Q., Paraizo, M. M., Ibañez, H. C., da Rocha, J. C. C., Pinto, E. M., de Andrade, D. P., Ibañez, M. V. C., Komechen, H., Figueiredo, M. M. O., Custódio, G., et al. (2022) · Cancers · doi:10.3390/cancers14123014 · Cited by 2
Li-Fraumeni Syndrome with Unusual Synchronous Malignancies: A Case Report
Mansor, E. A., Adamiak, A., & Asmis, T. R. (2024) · Case Reports in Oncology · doi:10.1159/000535099 · Cited by 2
Case series of Li-Fraumeni syndrome: carcinogenic mechanisms in breast cancer with TP53 pathogenic variant carriers
Hosonaga, M., Habano, E., Arakawa, H., Kaneko, K., Nakajima, T., Hayashi, N., Fukada, I., Nakamura, A., Haruyama, Y., Maeda, T., et al. (2024) · Breast Cancer · doi:10.1007/s12282-024-01612-3 · Cited by 2
A novel p.Gly187Arg TP53 variant appears to result in Li–Fraumeni syndrome
Doyle, M. R., & Johnston, J. M. (2018) · Pediatric Hematology and Oncology · doi:10.1080/08880018.2018.1502852 · Cited by 2
Uncommon Adrenal Tumors in Children and Adolescents
Ribeiro, R. C., Galindo, C. R., Pinto, E. M., Zambetti, G. P., & de Figueiredo, B. C. (2017) · Wiley eBooks · doi:10.1002/9781119196235.ch77 · Cited by 2
Genomic profile of two Brazilian choroid plexus tumors by whole-exome sequencingPreprint
Garcia, F. A. D. O., Evangelista, A. F., Mançano, B. M., Moreno, D. A., Berardinelli, G. N., de Paula, F. E., Antoniazzi, A. P., Júnior, C. A., Lombardi, I. A. S., Santana, I. V. V., et al. (2023) · Molecular Case Studies · doi:10.1101/mcs.a006245 · Cited by 2
A microglia clonal inflammatory disorder in Alzheimer’s DiseasePreprint
Vicario, R., Fragkogianni, S., Weber, L., Lazarov, T., Hu, Y., Hayashi, S. Y., Craddock, B. P., Socci, N. D., Alberdi, A., Baako, A., et al. (2024) · eLife · doi:10.7554/elife.96519.2 · Cited by 2
Identification and Characterization of Rare Pathogenic Gene tic Variants Associated with Breast Cancer Susceptibility in 1000 Genome and gnomAD PopulationPreprint
Yadav, K., & Prasad, A. (2025) · medRxiv · doi:10.1101/2025.08.30.25334747 · Cited by 2
Two cancer‐predisposing variants in one family: Incidental finding of a fumarate hydrogenase (FH) germline variant in a family with Li–Fraumeni syndrome
Pahl, L., Beier, R., Neuhoff, N. V., Auber, B., Höfs, M., Prott, E., Schlegelberger, B., Reinhardt, D., & Steinemann, D. (2018) · Pediatric Blood & Cancer · doi:10.1002/pbc.27254 · Cited by 1
Panel Testing for Hereditary Breast Cancer: More or Less?
Landry, K. K., & Wood, M. E. (2020) · Current Breast Cancer Reports · doi:10.1007/s12609-020-00361-4 · Cited by 1
Molecular Mechanisms of Early Breast Cancer
Ariyannur, P. S., & Srinivasalu, V. K. (2020) · Springer eBooks · doi:10.1007/978-981-15-6171-9_5 · Cited by 1
Case Report of an Unusual Tumor in an Adult With a TP53 Germline Mutation
Castiaux, J., Vandernoot, I., Dallemagne, J., Bruneau, M., Delaunoy, M., Peyrassol, X., Heimann, P., Wilde, V. D., & Wolfromm, A. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.10.001 · Cited by 1
Pedigree analysis exploring the inconsistency between diverse phenotypes and testing criteria for germline TP53 mutations in Chinese women with breast cancer
Huang, X., Chen, C., Lin, Y., Wang, C., Zhou, X., Xu, Y., Sun, Q., & Zhou, Y. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-024-07341-7 · Cited by 1
Osteosarcoma patient with Li-Fraumeni syndrome: the first case report in Vietnam
Le, T. T., Ha, T. S., To, L., Dang, Q. M., Bui, H. T. P., Tran, T. D., Vu, P. T., Giang, H. B., Trung, D. T., & Nguyen, X. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1458232 · Cited by 1
Heritable TP53-related cancer syndrome and medulloblastoma in children: diagnostic and screening issues
Dinikina, Y. V., Zheludkova, O., Maizenger, P. A., Nikitina, I. L., Bezyazychnaya, I. V., Радулеску, Г. Г., Leonova, I. A., Косенкова, Т. В., Образцова, Г. И., Bashnina, E. B., et al. (2024) · Pediatric Hematology/Oncology and Immunopathology · doi:10.24287/1726-1708-2024-23-3-91-101 · Cited by 1
Exploiting somatic oncogenic driver alterations in a patient with Li-Fraumeni syndrome– paving the path towards precision medicine: a case report
Seeling, C., Dahlum, S., Marienfeld, R. B., Jan, V., Rack, B. K., Gerstenmaier, U., Beer, A. J., Mayer‐Steinacker, R., Thaiss, W. M., Barth, T. F. E., et al. (2025) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-06077-7 · Cited by 1
A case of Li–Fraumeni syndrome caused by a 3.6 kb deletion in the TP53 gene suggested by additional data from the NCC Oncopanel
Souma, S., Ogawa, M., Ito, S., Yamaguchi, K., Fujimori, H., Asano, N., Ohnuki, K., Takeuchi, M., Otsuka, K., Shirota, H., et al. (2025) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaf011 · Cited by 1
Limiting surveillance in individuals with the Palestinian TP53 p. R181C founder variant—is it too soon to draw conclusions?
Omran, M., & Malkin, D. M. (2025) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaf009 · Cited by 1
Li-Fraumeni Syndrome : Current Strategies and Future Perspectives
Lee, J. W. (2025) · Journal of Korean Neurosurgical Society · doi:10.3340/jkns.2025.0050 · Cited by 1
The argument for screening programs in previvors with Li-Fraumeni syndrome
Omran, M., & Malkin, D. M. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2522943 · Cited by 1
Prolonged symptom duration and the potential for gradual progression in pediatric adrenocortical tumors: observations from the MET studies
Kuhlen, M., Wudy, S. A., Baumann, C., Vokuhl, C., Hartmann, M. F., Kunstreich, M., Claus, R., & Redlich, A. (2025) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2025-0198 · Cited by 1
Clinical TP53 genetic testing is recommended for HER2-positive breast cancer patients aged 35 or younger
Li, J., Chen, L., Chen, X., Huang, M., Guo, W., Chen, M., Lin, Y., Wang, Y., Cai, W., Qiu, Y., et al. (2025) · npj Genomic Medicine · doi:10.1038/s41525-025-00496-2 · Cited by 1
A Comprehensive Review of Somatic and Germline Biomarkers Associated with Childhood B-Cell Precursor Acute Lymphoblastic Leukemia: From Biological Significance to Precision Medicine Opportunities
Anaya, D. M., Ruiz, J. I. R., Navarrete-Meneses, M. D. P., & Pérez‐Vera, P. (2025) · Biomedicines · doi:10.3390/biomedicines13071626 · Cited by 1
Variation at the R181 Residue of p53 Confers Loss of p53 DNA Binding Cooperativity with the Retention of Mitochondria-Associated Apoptosis
Moses, R., Indeglia, A., Levine, A. S., Hausler, R. M., Kelly, G., Miller, S. A., Anez-Bruzual, I., Heller, M., Delgado, R., Orr, C., et al. (2026) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-26-0030 · Cited by 1
Exploring DNA topoisomerase II alpha in adrenocortical carcinoma through multi-omics analysis: a potential biomarker and therapeutic target
Lu, J., Deng, P., Wu, Z., Liang, Y., Zhuo, Y., Wu, Y., Liang, Y., Ye, J., Xie, W., Cai, Z., et al. (2025) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2025144 · Cited by 1
Understanding the epidemiology of gastric cancer: a review and case-only analysis from Italy
Collatuzzo, G., Fiorini, G., Renieri, T., Pavoni, M., Boccia, S., D’Errico, A., Vaira, D., & Boffetta, P. (2025) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000003064 · Cited by 1
A Novel Approach to Prognostic Factors and Risk Stratification in Pediatric AML: Case Report and Literature Review
Leśniak, M., Sekunda, A., Kamizela, E., Deleszkiewicz, P., Ozygała, A., Zawitkowska, J., & Lejman, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199269 · Cited by 1
Tumor Predisposition Syndromes
Robles, C., Laughlin, S., & Pai, V. (2025) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2025.09.006 · Cited by 1
Current state of diagnostic genetic testing in pediatric sarcoma: Survey and review by the Cancer Genomics Consortium Sarcoma Working Group
Schieffer, K. M., Bajaj, R., Koo, S. C., Lavoie, J., Lopez-Terrada, D. H., Lu, X., Luo, M., Phung, T. L., Smolarek, T. A., Sutcliffe, M. J., et al. (2025) · Cancer Genetics · doi:10.1016/j.cancergen.2025.10.106 · Cited by 1
Rare inherited bone marrow failure syndromes with a predisposition to malignant neoplasms
Vasileva, M. S., Maschan, A., & Novichkova, G. A. (2025) · Pediatric Hematology/Oncology and Immunopathology · doi:10.24287/j.999 · Cited by 1
Impact of Germline DNA Repair Mutations on Clonal Hematopoiesis and Myeloid Neoplasm Development
Fedorov, K., Luo, L. Y., Bick, A. G., & Savona, M. R. (2025) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-025-00768-9 · Cited by 1
The Main Cancer Theories in Focus
Paul, D. (2025) · Springer eBooks · doi:10.1007/978-3-032-08808-6_5 · Cited by 1
Radiotherapy in Li-Fraumeni Syndrome: From Biological Concern to Personalized Clinical Decision-Making
Mjabber, R. E., Alami, R., Filali, N., Bourial, A., Dahbi, Z., Kouhen, F., Ismaili, N., Majjaoui, S. E., & Naim, A. (2026) · Cureus · doi:10.7759/cureus.100978 · Cited by 1
Clinical Features and Treatment Strategies of Li‐Fraumeni Syndrome Patients With Inherited TP53 Mutations
Chen, K., Xu, Y., Song, B., Gu, Y., Xu, X., Cao, J., & Fang, M. (2026) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.70177 · Cited by 1
Moving Beyond Somatic Alterations: Uncovering the Germline Basis of Myeloid Malignancies
Younes, I. E., Nguyen, L., & Zhang, L. (2026) · Cancers · doi:10.3390/cancers18020240 · Cited by 1
Attenuated Li–Fraumeni syndrome with TP53 p.R181H in a Japanese patient with metastatic rectal adenocarcinoma: a case report
Kasahara, Y., Takahashi, M., Kawamura, Y., Aoki, Y., Niihori, T., Kawamura, M., Yamamoto, S., Shirota, H., Saijo, K., Imai, H., et al. (2026) · Familial Cancer · doi:10.1007/s10689-026-00529-4 · Cited by 1
Rare germline variants contribute to glioma predisposition: Whole-genome analysis of a regional cohort of glioma patients
Rosenbaum, A., Wibom, C., Suger, A. H., Pensch, R., Roy, A., Brännström, T., Rentoft, M., Forsberg‐Nilsson, K., Lindblad‐Toh, K., Lindström, S., et al. (2026) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdag038 · Cited by 1
SIGNIFIED: whole-body MRI screening in Li–Fraumeni syndrome in the UK
Finn, E., Sohaib, A., Withey, S. J., Infirri, S. S., Bunce, C., Clarke, C. S., Weng, J. Y., Scurr, E., Lee, R. W., Eeles, R. A., et al. (2026) · ESMO Open · doi:10.1016/j.esmoop.2025.106045 · Cited by 1
Germline and somatic genetic drivers of adrenocortical tumours
Bouys, L., & Bertherat, J. Y. (2026) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2026.102099 · Cited by 1
Surviving childhood cancer: the hidden threat of second malignancies
Shah, R., Yedururi, S., Morani, R. A., Arora, I., Austin, M., Ramani, N. S., Herzog, C. E., & Bhosale, P. (2026) · Cancer Imaging · doi:10.1186/s40644-025-00933-6 · Cited by 1
Clinical and genetic features of patients with Li–Fraumeni syndrome: experience of Research Institute of Pediatric Oncology and Hematology named after Academician of the Russian Academy of Medical Sciences L.A. Durnov
Kazubskaya, T. P., Зеленова, Е. Е., Trofimov, E. I., Kozlova, V. M., Романцова, О. М., Rubanskaya, M. V., Semenova, V. V., Белышева, Т. С., Акшенович, К. П., Suleymanova, A. M., et al. (2026) · Russian Journal of Pediatric Hematology and Oncology · doi:10.21682/2311-1267-2026-13-1-12-23 · Cited by 1
Shared inheritance reveals landscape of somatic and germline cancer risk in TP53
MacGregor, H. A. J., Blundell, J. R., & Easton, D. F. (2026) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2026.07.011 · Cited by 2
Genetic Evaluation and Testing
Hunter, C. (2016) · Springer eBooks · doi:10.1007/978-3-319-19437-0_4 · Cited by 1
Hereditary Breast Cancer Genetics and Risk Prediction Techniques
Carley, H., & Kulkarni, A. (2017) · Springer eBooks · doi:10.1007/978-3-319-56673-3_5 · Cited by 1
Gray Zone Lymphoma Arising in the Neck of a Teenager With a Germline Mutation in TP53
Gatineau-Sailliant, S., Turcotte, K., Quintal, M., Turpin, S., Champagne, J., Petrella, T., Roussy, M., Cellot, S., & Soglio, D. B. D. (2018) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000001308 · Cited by 1
The effect of smoking and TP53 mutations on molecular-targeted therapy in lung adenocarcinoma patients
Okuda, K., Haneda, H., Yokota, K., Tatematsu, T., & Nakanishi, R. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.09.43 · Cited by 1
Oncogenética: cánceres de mama hereditarios
Perre, P. V., Imbert‐Bouteille, M., & Pujol, P. (2019) · EMC - Ginecología-Obstetricia · doi:10.1016/s1283-081x(19)42497-1 · Cited by 1
Neuroradiology Manifestations of Li-Fraumeni Syndrome: Epidemiology, Genetics, Imaging Findings, and Management
Naganawa, S., Donohue, T., Capizzano, A. A., Ota, Y., Kim, J., Srinivasan, A., & Moritani, T. (2020) · Neurographics · doi:10.3174/ng.2000003 · Cited by 1
In cis TP53 and RAD51C pathogenic variants may predispose to sebaceous gland carcinomas
Duc, D. L., Hentschel, J., Neuser, S., Stiller, M., Meier, C., Jäger, E., Jamra, R. A., Platzer, K., Monecke, A., Ziemer, M., et al. (2020) · European Journal of Human Genetics · doi:10.1038/s41431-020-00781-x · Cited by 1
Clinical and genetic evidence and population evidence
Charames, G. S., Sabatini, P. J. B., & Watkins, N. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820519-8.00021-1 · Cited by 1
A Unique Case of Bilateral Thalamic High-Grade Glioma in a Pediatric Patient with LI-Fraumeni Syndrome: Case Presentation and Review of the Literature
Messina, R., Cazzato, G., Perillo, T., Stagno, V., Blè, V., Resta, M., Leonardis, F. D., Santoro, N., Signorelli, F., & Ingravallo, G. (2021) · Neurology International · doi:10.3390/neurolint13020017 · Cited by 1
Recognition of Cancer Predisposition Syndromes
Reichman, L., & Goudie, C. (2021) · Springer eBooks · doi:10.1007/978-3-030-74448-9_16 · Cited by 1
Actualidad del melanoma dentro del espectro clínico del síndrome de Li Fraumeni
Tulcán, E. Y. B., & Pérez, A. V. (2022) · Piel · doi:10.1016/j.piel.2021.11.012 · Cited by 1
A Four-Year-Old Female With a Rare P53 Gene Mutation Diagnosed With Li-Fraumeni Syndrome and Concomitant Metastatic Rhabdomyosarcoma: A Case Report
Donato, U. M., Donato, S., & Galligan, A. J. (2022) · Cureus · doi:10.7759/cureus.27009 · Cited by 1
Lessons Learned in Practice with Li-Fraumeni Syndrome: LFS-Related Breast Cancer Treatment Strategy and Establishment of a Surveillance System
Sasaki, R., Horimoto, Y., Saeki, H., SATO, S., Sano, K., Shikama, N., UENO, M., Saito, M., & Arai, M. (2022) · Juntendō Igaku/Juntendo igaku · doi:10.14789/jmj.jmj22-0012-cr · Cited by 1
A case report: invasive ductal carcinoma in mosaic Li-Fraumeni syndrome
Wenger, D. M., Kurumety, S. K., & Aydi, Z. B. (2022) · Journal of Surgical Case Reports · doi:10.1093/jscr/rjac408 · Cited by 1
About a Large Botryoid Rhabdomyosarcoma in a Little Girl: Management Difficulties and Literature Review
Mian, D. B., Loué, V., & Koui, S. (2023) · Case Reports in Obstetrics and Gynecology · doi:10.1155/2023/4789851 · Cited by 1
Imaging Recommendations for Diagnosis, Staging, and Management of Hereditary Malignancies
Majithia, J., Mahajan, A., Vaish, R., Prakash, G. J., Patwardhan, S., & Sarin, R. (2023) · Indian Journal of Medical and Paediatric Oncology · doi:10.1055/s-0042-1760325 · Cited by 1
Recent Advances in Diagnostic and Surveillance Strategies for Childhood Cancer Predisposition Syndromes
Yoo, J. W. (2023) · Imsang soa hyeoraek jong-yang/Imsang soa hyeol'aeg jong'yang/Clinical pediatric hematology-oncology · doi:10.15264/cpho.2023.30.1.1 · Cited by 1
Germline Predisposition to Myelodysplastic Syndromes
Gener‐Ricos, G., Gerstein, Y. S., Hammond, D. E., & Dinardo, C. D. (2023) · The Cancer Journal · doi:10.1097/ppo.0000000000000660 · Cited by 1
Molecular reclassification reveals low prevalence of germline predisposition in children with ependymoma
Foss-Skiftesvik, J., Mathiasen, R., Hansen, T. V. O., Wadt, K., Schmiegelow, K., & Stoltze, U. K. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01594-x · Cited by 1
Brain and/or Spinal Cord Tumors Accompanied with Other Diseases or Syndromes
Capitanio, J. F., & Mortini, P. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-23705-8_25 · Cited by 1
Scylla and Charybdis: Unpalatable choices in managing hypodiploid acute lymphoblastic leukemia
Colgan, J. N., Fuentes-Bolanos, N., Barbaric, D., Dalla‐Pozza, L., Mitchell, R., Samarasinghe, S., Schrappe, M., Tucker, K. M., Schmiegelow, K., & Trahair, T. N. (2023) · EJC Paediatric Oncology · doi:10.1016/j.ejcped.2023.100133 · Cited by 1
Phenotype analysis of families with TP53 germline variants at the Center for Familial Breast and Ovarian Cancer, Cologne
Kast, K., Rhiem, K., Larsen, M., Wappenschmidt, B., & Schmutzler, R. K. (2024) · Cancer Medicine · doi:10.1002/cam4.6920 · Cited by 1
Laparoscopic resection of liver PEComa associated with Li‑Fraumeni syndrome: A case report
Takada, R., TAKAHASHI, M., Hayashi, T., Higashihara, T., Morita, Y., Inoue, D., Okada, H., & Araki, J. (2024) · Biomedical Reports · doi:10.3892/br.2024.1842 · Cited by 1
New Germline TP53 Variant Detected After Radiotherapy‐Induced Angiosarcoma of the Chest Wall in a Previously Treated Breast Cancer Patient: A Case Report and Review of Li–Fraumeni Syndrome and Radiotherapy‐Induced Sarcoma
David, B. B. L., Silva, S. S. A., Dinoá, V., Ferreira, T. D., Pereira, E. M., Fernandes, C. D. B., & Garicochea, B. (2024) · Case Reports in Oncological Medicine · doi:10.1155/crom/6640468 · Cited by 1
Genetic Predisposition for Acute Lymphoblastic Leukemia
Stoltze, U. K., Brozou, T., Schmiegelow, K., & Borkhardt, A. (2024) · Pediatric oncology · doi:10.1007/978-3-031-71180-0_1 · Cited by 1
Evaluation of prognostic factors in advanced pediatric ACC
Riedmeier, M., Agarwal, S., Antonini, S. R. R., Ekinci, S., Fassnacht, M., de Figueiredo, B. C., Härtel, C., Meena, J. P., Marks, S. D., Munarin, J., et al. (2025) · Endocrine Related Cancer · doi:10.1530/erc-24-0135 · Cited by 1
P53 in Head and Neck Squamous Cell Carcinoma
Parameswaran, J., & Burtness, B. A. (2018) · Current cancer research · doi:10.1007/978-3-319-78762-6_9 · Cited by 1
Seltene Tumoren als Leitsymptom hereditärer Tumorsyndrome
Perne, C., Steinke‐Lange, V., Aretz, S., & Spier, I. (2020) · best practice onkologie · doi:10.1007/s11654-020-00269-6 · Cited by 1
Report of 2 Pediatric Cases With Li-Fraumeni Syndrome Related Malignancy in a Family
Takeoka, M., Toyoda, H., Hirayama, J., Suzuki, N., Hanaki, R., Amano, K., Iwamoto, S., & Hirayama, M. (2020) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000001862 · Cited by 1
Pre- and Post-Zygotic TP53 De Novo Mutations in SHH-Medulloblastoma
Azzollini, J., Schiavello, E., Buttarelli, F. R., Clerici, C. A., Tizzoni, L., Vecchi, G. D., Capra, F., Pisati, F., Biassoni, V., Runza, L., et al. (2020) · Cancers · doi:10.3390/cancers12092503 · Cited by 1
Radioprotection Issues for Women with Hereditary Predisposition for Breast Cancer
Colin, C., Foray, N., & Bourguignon, M. (2020) · Springer eBooks · doi:10.1007/978-3-030-41207-4_12 · Cited by 1
A Novel Germline TP53 Mutation in a Patient With Li-Fraumeni Syndrome: Resolving a Variant of Uncertain Significance
Douglass, D. P., Stine, K. C., & Farrar, J. E. (2021) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000002115 · Cited by 1

Authors: Bougeard, G., Renaux-Petel, M., Flaman, J.-M., Charbonnier, C., Fermey, P., Belotti, M., Gauthier-Villars, M., Stoppa-Lyonnet, D., Consolino, E., Brugières, L., Caron, O., Benusiglio, P. R., Bressac-de Paillerets, B., Bonadona, V., Bonaïti-Pellié, C., Tinat, J., Baert-Desurmont, S., & Frebourg, T.
Affiliations: Inserm (FR)
Gaëlle Bougeard, Mariette Renaux-Petel, Jean-Michel Flaman, Camille Charbonnier, Pierre Fermey, Julie Tinat, Stéphanie Baert-Desurmont, Thierry Frebourg, Institut National de la Santé et de la Recherche Médicale (Inserm) U1079, University of Rouen, Institute for Research and Innovation in Biomedicine; Julie Tinat, Stéphanie Baert-Desurmont, Thierry Frebourg, University Hospital, Rouen; Muriel Belotti, Marion Gauthier-Villars, Dominique Stoppa-Lyonnet, Curie Institute, Paris; Emilie Consolino, Laurence...
ORCID: Bougeard, Gaëlle
Flaman, Jean-Michel
Charbonnier, Camille
Brugières, Laurence
Caron, Olivier
Benusiglio, Patrick R.
Bonadona, Valérie
Tinat, Julie
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2015-07-20
Volume: 33
Issue: 21
Pages: 2345-2352
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2014.59.5728
OpenAlex: W2095770043
Cited by: 760
References: 42
Citations by year: 2026: 68 · 2025: 85 · 2024: 95 · 2023: 67 · 2022: 82 · 2021: 81 · 2020: 78 · 2019: 59 · 2018: 42 · 2017: 64 · 2016: 30 · 2015: 9
FWCI: 21.11
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
HAL (submittedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Keywords: Li-Fraumeni syndrome, germline TP53 mutation, cancer susceptibility, multiple primary neoplasms, childhood tumors, osteosarcoma, adrenocortical carcinoma, choroid plexus carcinoma, breast cancer, soft tissue sarcoma, central nervous system tumors, loss-of-function mutations, genome rearrangement, mutation classification
MeSH terms: Adolescent, Adult, Female, France, Genetic Testing, Genotype, Humans, Male, Phenotype, Tumor Suppressor Protein p53, Li-Fraumeni Syndrome, Sequence Analysis, DNA, Age of Onset, Germ-Line Mutation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks